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1. Introduction 
Sudden cardiac death (SCD) is a major public health issue with an estimated annual 
incidence of 300,000 - 400,000 cases per year. The ACC/AHA/ESC 2006 guidelines define 
SCD as “death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia 
occurring within an hour of the onset of symptoms”(Zipes et al. 2006). Most of the patients 
experiencing sudden cardiac arrest have an ejection fraction (LVEF) more than 50%, with the 
majority of these patients having a history of coronary artery disease (CAD). However, the 
risk of death in patients with LVEF of less than 35% is higher than patients with better 
preserved LVEF (Gorgels et al. 2003). Beta blocker therapy, Angiotensin enzymes inhibitors 
(ACE-I), angtiotensin receptor blockers as well as aldosteron antagonists have been shown 
to decrease the risk of sudden cardiac death especially in post myocardial infarction patients 
(Seidl et al. 1998; Domanski et al. 1999; Pitt et al. 2003; McMurray et al. 2005). In contrast 
antiarrhythmic drug therapy doesn’t prevent sudden cardiac death in patients with 
cardiomyopathy. The focus of this chapter is to review the major implantable cardioverter 
defibrillator (ICD) and cardiac resynchronization therapy trials and their effects on sudden 
cardiac death prevention in patients with cardiomyopathy who are receiving optimal 
medical therapy.  
2. Trials examining the benefits of ICD therapy in sudden cardiac death 
prevention 
2.1 Secondary prevention trials of defibrillator therapy 
The earlier trials examined the highest risk population of patients who had cardiac arrest 
due to ventricular fibrillation or sustained ventricular tachycardia (VT) and syncope. These 
trials helped establish the benefit of ICD therapy in prevention of sudden cardiac death as 
well as identify patients who are at high risk of dying suddenly and might benefit from ICD 
therapy as a primary prevention approach.  
The first trial is the Antiarrhythmic versus Implantable Defibrillators Trial (AVID). Patients 
were included if they were resuscitated from VT, had sustained VT with syncope or had 
sustained VT with LVEF < 40% and symptoms suggestive of hemodynamic compromise 
(angina or congestive heart failure or near syncope) (AVID 1997). Patients were excluded if the 
ventricular arrhythmia was due to a reversible cause, but those patients were followed in a 
registry. AVID enrolled 1016 patients and the primary end point was all cause mortality. Over 
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80% of the patients randomized to antiarrhythmic therapy (total of 509 patients) were on 
Amiodarone at end of follow up. AVID was terminated early when patients with ICD therapy 
(n=506) had a 38% reduction in all cause mortality compared to patients with antiarrhythmic 
drug therapy (HR 0.62, 95% CI of 0.47 to 0.81). Analysis of the AVID trial showed that patients 
with LVEF < 35% who received an ICD had significant reduction of sudden cardiac death 
while patients with LVEF > 35% who received an ICD did not see significant benefit compared 
to the antiarrhythmic drug therapy group (Domanski et al. 1999).  
The patients with a reversible cause of ventricular arrhythmia who were not randomized 
were followed in a registry. These patients were in general younger, had a better mean 
LVEF and were more likely to have history of coronary artery disease and had underwent 
revascularization. Most of the reversible causes were due to ischemia or myocardial 
infarction (65%) or due to electrolytes imbalance (10%). Patients who were categorized as 
having VT/VF due to reversible causes had similar if not higher risk of sudden cardiac 
death compared to patients with no identifiable reversible cause(Wyse et al. 2001). Careful 
follow up and aggressive assessment for this patient group is advised.  
The second study is the Canadian Implantable Defibrillator Study (CIDS), which enrolled 
659 patients who had VT, sustained VT with syncope or sustained VT with LVEF < 35%. 
Patients were excluded if they had recent myocardial infarction (MI) with in the past 72 
hours or if they had electrolytes imbalance. Primary end point was all cause mortality. The 
patients were followed for an average of 36 months. There was a 20% relative risk reduction 
of death with ICD therapy compared to amiodarone (p=0.14)(Connolly et al. 2000). Analysis 
of CIDS showed that patients with low LVEF benefited from ICD therapy more than patient 
with better-preserved LVEF(O'Brien et al. 2001).  
The third study is the Cardiac Arrest Study Hamburg (CASH), which was a small trial 
randomizing 288 patients to ICD therapy with drug therapy. Inclusion criteria included 
patients successfully resuscitated from cardiac arrest due to documented sustained 
ventricular arrhythmia. Exclusion criteria included patients who had a cardiac arrest within 
72 hours after MI or cardiac surgery or if they had a reversible cause due to electrolyte 
abnormality or proarrhythmic drug. There was a trend towards lower death with ICD 
therapy compared to drug therapy (23% relative risk reduction, p=0.16). Average follow up 
was 57 months. The lack of benefit in the CASH trial might be due to the fact that it had a 
small study population and better mean LVEF (45% ±18%) compared to the AVID trial(Kuck 
et al. 2000). Also, 44% of patient in CASH study had epicardial lead implantation as 
compared to only 4% in the AVID trial.  
A pooled analysis of these trials demonstrated that all cause mortality was reduced by 27% 
(HR of ICD compared to Amiodarone of 0.73, 95% CI 0.60-0.87, p<0.001) (Connolly et al. 
2000). Arrhythmic death was also reduced in the ICD group compared to the Amiodarone 
group (HR 0.49, 95% CI of 0.36 to 0.67, p<0.001). The metaanalysis also showed that patients 
with LVEF <35% had a significant benefit from ICD therapy compared to Amiodarone (HR 
0.66, 95% CI of 0.53 to 0.83) while patients with LVEF >35% had no significant benefit from 
ICD therapy compared to Amiodarone therapy (HR of 1.2, 95% CI of 0.81 to 1.76). 
Furthermore, patients receiving epicardial lead systems had no benefit from ICD therapy 
compared to Amiodarone (HR 1.52, 95% CI of 0.92 to 2.50), while patients with transvenous 
lead had the most benefit (HR 0.69, 95% CI of 0.56 to 0.85). The three randomized trials 
examining the benefit of implantable cardioverter defibrillator (ICD) therapy in patients 
who survived cardiac arrest are summarized in Table 1. 
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Trial  N Inclusion Criteria 
Primary 
Endpoint 
Age 
Mean 
LVEF 
HR (95% 
Confidence 
Interval) 
P 
Value 
Antiarrhythmic
s versus 
Implantable 
Defibrillators 
(AVID) (1016 
patients) 
1016 
Resuscitated VF, 
sustained VT and 
syncope or sustained 
VT with LVEF < 40% 
and severe symptoms 
All cause 
mortality 
65 35% 
0.62 
(0.47-0.81) 
0.02 
Canadian 
Implatable 
Defibrillator 
Study (CIDS) 
(659 patients) 
659 
Resuscitated VF, 
sustained VT and 
syncope or sustained 
VT with LVEF < 35% 
or unmonitored 
syncope with 
subsequent inducible 
VT or sustained VT 
All cause 
mortality 
64 34% 
0.82  
(0.60 to 1.10) 
0.14 
Cardiac Arrest 
Study 
Hamburg 
(CASH) 
288 
cardiac arrest due to 
documented sustained 
ventricular arrhythmia 
All cause 
mortality 
58 45%  0.16 
Table 1. Secondary prevention trials of ICD therapy. VT is for ventricular tachycardia, VF is 
for Ventricular Fibrillation, LVEF is for left Ventricular ejection Fraction. HR is for hazard 
Ratio, CI is confidence interval.  
These trials established the benefits of ICD therapy in patients who survived cardiac arrest 
in the absence of reversible causes. Patients with reversible causes of the cardiac arrest 
remain high risk and should be followed closely. Even though the metaanalysis of these 
trials showed no benefits of ICD therapy in patients with LVEF >35%, this is not reflected in 
the guidelines due to the fact that LVEF was not an entry criterion in these trials. 
Furthermore, the mean time of cardiac arrest and measurement of LVEF was 3 days in the 
AVID trial, and the LVEF shortly after cardiac arrest might be depressed from myocardial 
injury and might improve over time. Table 2 lists current guidelines for ICD therapy.  
 
Class I: (General agreement of benefit with ICD therapy) 
1. ICD therapy is indicated in patients who are survivors of cardiac arrest due to VF or 
hemodynamically unstable sustained VT after evaluation to define the cause of the 
event and to exclude any completely reversible causes.  
2. ICD therapy is indicated in patients with structural heart disease and spontaneous 
sustained VT, whether hemodynamically stable or unstable.  
3. ICD therapy is indicated in patients with syncope of undetermined origin with 
clinically relevant, hemodynamically significant sustained VT or VF induced at 
electrophysiological study.  
4. ICD therapy is indicated in patients with LVEF less than or equal to 35% due to prior 
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MI who are at least 40 days post-MI and are in NYHA functional Class II or III.  
5. ICD therapy is indicated in patients with nonischemic dilated cardiomyopathy who 
have an LVEF less than or equal to 35% and who are in NYHA functional Class II or 
III.  
6. ICD therapy is indicated in patients with LV dysfunction due to prior MI who are at 
least 40 days post-MI, have an LVEF less than or equal to 30%, and are in NYHA 
functional Class I.  
7. ICD therapy is indicated in patients with nonsustained VT due to prior MI, LVEF 
less than or equal to 40%, and inducible VF or sustained VT at electrophysiological 
study.  
Class IIa (Weight of evidence is in favor of usefulness of ICD therapy)  
1. ICD implantation is reasonable for patients with unexplained syncope, significant LV 
dysfunction, and non-ischemic dilated cardiomyopathy.  
2. ICD implantation is reasonable for patients with sustained VT and normal or near-
normal ventricular function.  
3. ICD implantation is reasonable for patients with hypertrophic cardiomyopathy 
(HCM) who have 1 or more major risk factors for SCD. [Major risk factors for SCD in 
patients with HCM are: prior cardiac arrest, spontaneous sustained VT, spontaneous 
non-sustained VT, Family history of SCD, LV thickness ≥ 30 mm and abnormal blood 
pressure response to exercise] 
4. ICD implantation is reasonable for the prevention of SCD in patients with ARVD/C 
who have 1 or more risk factors for SCD. [Risk factors for SCD in patients with 
ARVD/C are: prior cardiac arrest, spontaneous sustained VT, spontaneous non-
sustained VT, evidence of extensive RV disease, LV involvement, presentation with 
polymorphic VT and RV apical aneurysm and induction of VT during 
electrophysiologic testing] 
5. ICD implantation is reasonable to reduce SCD in patients with long-QT syndrome 
who are experiencing syncope and/or VT while receiving beta blockers.  
6. ICD implantation is reasonable for non hospitalized patients awaiting 
transplantation.  
7. ICD implantation is reasonable for patients with Brugada syndrome who have had 
syncope.  
8. ICD implantation is reasonable for patients with Brugada syndrome who have 
documented VT that has not resulted in cardiac arrest.  
9. ICD implantation is reasonable for patients with catecholaminergic polymorphic VT 
who have syncope and/or documented sustained VT while receiving beta blockers.  
10. ICD implantation is reasonable for patients with cardiac sarcoidosis, giant cell 
myocarditis, or Chagas disease.  
Class IIb (Efficacy of the ICD therapy is less well established) 
1. ICD therapy may be considered in patients with non-ischemic heart disease who 
have an LVEF of less than or equal to 35% and who are in NYHA functional Class I.  
2. ICD therapy may be considered for patients with long-QT syndrome and risk factors 
for SCD.  
3. ICD therapy may be considered in patients with syncope and advanced structural 
heart disease in whom thorough invasive and noninvasive investigations have failed 
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to define a cause.  
4. ICD therapy may be considered in patients with a familial cardiomyopathy 
associated with sudden death.  
5. ICD therapy may be considered in patients with LV noncompaction.  
Class III (General agreement that an ICD is not effective and may be harmful) 
1. ICD therapy is not indicated for patients who do not have a reasonable expectation 
of survival with an acceptable functional status for at least 1 year, even if they meet 
ICD implantation criteria specified in the Class I, IIa, and IIb recommendations 
above.  
2. ICD therapy is not indicated for patients with incessant VT or VF.  
3. ICD therapy is not indicated in patients with significant psychiatric illnesses that 
may be aggravated by device implantation or that may preclude systematic follow-
up.  
4. ICD therapy is not indicated for NYHA Class IV patients with drug-refractory 
congestive heart failure who are not candidates for cardiac transplantation or CRT-D.  
5. ICD therapy is not indicated for syncope of undetermined cause in a patient without 
inducible ventricular tachyarrhythmias and without structural heart disease.  
6. ICD therapy is not indicated when VF or VT is amenable to surgical or catheter 
ablation (e.g., atrial arrhythmias associated with the Wolff-Parkinson-White 
syndrome, RV or LV outflow tract VT, idiopathic VT, or fascicular VT in the absence 
of structural heart disease).  
7. ICD therapy is not indicated for patients with ventricular tachyarrhythmias due to a 
completely reversible disorder in the absence of structural heart disease (e.g., 
electrolyte imbalance, drugs, or trauma).  
Table 2. Recommendations for ICD therapy based on the ACC/AHA/HRS 2008 Guidelines 
for Device Based Therapy.  
2.2 Primary prevention trials of defibrillator therapy 
2.2.1 Primary prevention of SCD in patients with ischemic cardiomyopathy with and 
without prior myocardial infarction 
The earlier primary prevention trials used electrophysiologic testing as well as a reduced 
LVEF as part of entry criterion. Electrophysiologic testing (EP study) was thought to be a 
reliable method of risk stratification of patients with coronary artery disease (CAD) who 
survived myocardial infarction.  
The First of these trials is the First Multicenter Automatic Defibrillator Implantation Trial 
(MADIT- I) which compared ICD therapy to conventional care in 196 patients post MI, LVEF 
< 35%, non-sustained VT on ambulatory monitoring and inducible VT by programmed 
electrical stimulation and failure of intravenous procainamide to prevent inducibility (Moss et 
al. 1996). Patients were excluded if they had prior cardiac arrest or syncope due to ventricular 
tachycardia (VT) not related to myocardial infarction (MI). Patients were also excluded if they 
had suffered myocardial infarction within 3 weeks of randomization, had coronary artery 
bypass surgery within 2 months of randomization or if they had angioplasty within 3 months 
of randomization. MADIT I started enrolling patients in December 1990, with only 
transthoracic implantation of ICD was available at the time. Nonthoracotomy transvenous 
leads were implanted after being approved in August of 1993. Of the 196 patients enrolled, 95 
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patients were assigned to the ICD group and 101 patients were assigned to the conventional 
medical therapy group (which also included use of antiarrhythmic drugs). Primary endpoint 
was all cause mortality. After a mean follow up of 27 months, patients assigned to the ICD 
group had lower mortality than patients assigned to the conventional treatment group 
(Hazard Ratio (HR) of 0.46, 95% confidence interval (CI) 0.26 to 0.82, p=0.009). The interval 
from last MI was > 6 months in 75% of patients in each treatment group. The benefit of ICD 
was similar in patients with thoracotomy and non-thoracotomy ICD implantation (p=0.78). 
MADIT-I trail was the first trail to include patients who had purely low LVEF and inducible 
non-suppressible sustained ventricular arrhythmias during electrophysiologic testing.  
The First Multicenter Unsustained Tachycardia Trial (MUSTT-I) trial was designed to 
determine whether inducibilty of VT identified risk of sudden cardiac death in patients with 
LVEF < 40%, prior myocardial infarction and non-sustained VT documented more than 4 days 
after MI. Patients were enrolled if they had a positive electrophysiology study (defined as an 
inducible monomorphic VT or inducible polymorphic VT with one or two extrastimuli). Those 
with negative EP study were followed in a registry. A total of 704 patients with positive EP 
study were randomized to electrophysiologic guided antiarrhythmic therapy (which included 
a drug or implantation of an ICD) versus best medial therapy (mainly beta blockers and 
angiotensin enzyme inhibitors but no antiarrhythmic drug therapy) (Buxton et al. 1999). 
Patients who failed suppression of inducibility of the ventricular arrhythmia after at least one 
antiarrhythmic drug trial could receive an ICD. The ICD implantation was not randomized in 
MUSTT-I. The primary endpoint was cardiac arrest or death from arrhythmia. Secondary 
endpoints included death from all causes, death from cardiac causes and spontaneous 
sustained VT. Over a follow up period of 39 months, patients assigned to electrophysiologic 
testing (n=351) had lower risk of arrhythmic death or cardiac arrest compared to patients 
receiving best medical therapy (n=353) (Relative risk 0.73, 95% CI 0.53 to 0.99, p =0.04). This is 
mostly attributable to lower risk of arrhythmic death or cardiac arrest in patients receiving an 
ICD compared to patients not receiving an ICD (relative risk 0.24, 95% CI of 0.13 to 0.45, p< 
0.001). Patients who received an ICD had a lower risk of all cause mortality compared to 
patients with electrophysiology guided therapy who received antiarrhythmic drugs only 
(Relative risk 0.42, 95% CI of 0.29 to 0.61) This remained significant even after adjusting for all 
other clinical variables (Figure 1). 
MUSTT-I showed that patients who had an inducible VT that was suppressed with 
antiarrhythmic drugs did not have any mortality benefit.  
Patients who were screened for MUSTT-I but had a negative EP study were followed in a 
registry. Data was available for 1397 patients after 39 months of follow up. Total mortality was 
compared in this registry with the 353 patients in MUSTT-I with positive EP study that were 
assigned to best medical therapy. Only 35% of patients in the registry were on beta blockers 
compared to 51% of patients with inducible arrhythmias assigned to no antiarrhythmic therapy. 
The rate of used of ACE-I was similar (72% and 77% respectively). At 39 months, mortality was 
higher in patients with positive EP study assigned to best medical therapy (48%) compared to 
the patients with negative EP study in the registry (44%), (unadjusted p=0.09, adjusted p<0.001 
for other clinical factors including use of beta blockers). Even though this difference was 
statistically significant, the absolute difference of 4% over 5 years is not clinically meaningful. 
Given these results as well as the consistency of LVEF <35% to predict a mortality benefit from 
ICD therapy, Electrophysiologic testing is not routinely performed in patients with coronary 
artery disease and LVEF < 35% as a risk stratifying tool. (Buxton et al. 2000).  
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Fig. 1. Kaplan- Meier Estimates of the Rates of Death from All Causes. EPG denotes 
electrophysiologically guided. (From Buxton, A. E., Lee, K. L., Fisher, J. D., et al. (1999). "A 
randomized study of the prevention of sudden death in patients with coronary artery 
disease. Multicenter Unsustained Tachycardia Trial Investigators." New England Journal of 
Medicine, Vol. 341, No.25, (December, 1999): pp. 1882-1890, ISSN 0028-4793, with 
permission) 
The Coronary Artery Bypass Graft Patch and The Second Multicenter Automatic 
Defibrillator Implantation Trial (MADIT- II) trials examined the benefits of ICD therapy in 
patients with reduced LVEF months after myocardial infarction and did not include 
electrophysiologic testing or arrhythmia suppression as part of entry criterion. The 
Coronary Artery Bypass Graft-Patch Trial (CABG-Patch) randomized 1055 patients 
undergoing coronary artery bypass surgery, LVEF <36% and positive signal-averaged 
electrocardiograms to receive ICD therapy (n=446) or conventional medical therapy (n=454) 
(Bigger 1997). Only 50% of the patients had prior myocardial infarction but all the patients 
received epicardial ICD systems. ICD therapy showed no survival benefit over conventional 
medical therapy (HR 1.06, 95% CI of 0.81 to 1.42, p=0.64). The lack of benefit of ICD therapy 
in this trial could be due to the methods used for patient selection, but most likely is due to 
the effects of complete revascularization on the risk of sudden cardiac death. In a 
subanalysis of Studies of Left Ventricular Dysfunction (SOLVD) trial, CABG was found to 
be associated with a 36% relative risk reduction of all cause mortality and a 46% reduction of 
sudden cardiac death regardless of the severity of heart failure or the decrease in the LVEF. 
This might have contributed to the lack of benefit from ICD early after coronary artery 
bypass surgery (Veenhuyzen et al. 2001).  
The Second Multicenter Automatic Defibrillator Implantation Trial (MADIT- II) 
randomized 1232 patients in a 3:2 fashion with LVEF < 30% and prior MI to receive an ICD 
(n=742) compared to medical therapy (n=490). Patients were excluded if they had a recent MI 
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(<1 month), if they had revascularization in the past 3 months prior to randomization or if they 
were New York Heart Association (NYHA) class IV at enrollment. Mean follow up was for 30 
months and primary end point was all cause mortality. ICD therapy was associated with a 
31% reduction in relative risk of death at 20 months (HR 0.69, 95% confidence interval of 0.53 
to 0.93, p = 0.02) (Moss et al. 2002). There was no difference in subgroup analysis based on age, 
gender, ejection fraction, QRS duration as well as NYHA class in terms of ICD benefit. 
All ICD implantations were transvenous lead systems. No deaths were related to the 
implantation procedure and the complication of lead implantation was 1.8% and infection 
rate was 0.7%. Analysis of the mortality events showed that ICD therapy mainly prevented 
sudden cardiac death (HR 0.33, 95% CI of 0.2 to 0.53, p<0.001) but did not affect non-sudden 
cardiac death (p=0.32).  
Even though MADIT-II did not require electrophysiologic testing as an entry criterion, the 
investigators sought to evaluate the predictive value of EP study to predict mortality and 
ICD efficacy as a pre-specified secondary endpoint. Patients assigned to the ICD group were 
encouraged to undergo an EP study and they received the ICD regardless of the results of 
the electrophysiologic testing. Of the 720 patients who received an ICD, only 593 patients 
underwent EP testing. A positive EP study was defined as sustained monomorphic or 
polymorphic VT induced with 3 or fewer extrastimuli or VF induced with 2 or fewer 
extrastimuli. A positive EP study according to this standard protocol did not predict the pre-
specified primary endpoint of spontaneous VT or VF requiring treatment by the ICD 
(p=0.28). Patients with inducible VT were more likely to have VT during follow up (0.023) 
compared to patients with no inducible VT (Daubert et al. 2006). This confirms the findings 
of MUSTT-I trial in regards to the utility of EP testing in risk stratifying patients with 
coronary artery disease and LVEF < 35%.  
Another subanalysis of MADIT-II trial showed that patients with ICD therapy who 
underwent coronary revascularization within 6 months of randomization had no survival 
benefit from ICD therapy compared to patients in the conventional treatment group (HR 
= 1.19; p = 0.76), while patients with ICD therapy who were randomized > 6 months after 
coronary revascularization had significant survival benefit from ICD therapy (HR =0.64, p 
= 0.01) after adjusting for other important clinical variables (Goldenberg et al. 2006). 
Furthermore, mortality risk in patients in MADIT II was shown to be time dependent, 
with benefit extending even for patients who had remote MI (>15 years) (Wilber et al. 
2004). Two studies were conducted examine the benefits of ICD therapy early after 
myocardial infarction (MI). The first is The Defibrillators in Acute Myocardial Infarction 
Trial (DINAMIT) which was designed to evaluate the potential for ICD benefit early (6 to 
40 days) after a MI in patients with LVEF <35%, and abnormal autonomic tone [high 
resting heart rate over 80 beats per minutes (bpm) or low heart rate variability]. Patients 
were excluded if they had three-vessel coronary intervention, if they already had an ICD 
or if they were planned to undergo coronary artery bypass graft surgery (CABG). A total 
of 647 patients were randomized to optimal medical therapy (n=342) or ICD therapy 
(n=332) (Hohnloser et al. 2004). The primary end point was all cause mortality and the 
secondary end point was arrhythmic death. After a mean follow up of 30 months, there 
was no overall survival benefit attributable to early implantation of an ICD compared to 
medical therapy [HR 1.08; 95% confidence interval (CI), 0.76 to 1.55; P=0.66]. The ICD 
group had less arrhythmic death compared to the medical therapy group (HR in the ICD 
group, 0.42; 95% CI, 0.22 to 0.83; P=0.009). There was an increase in non-sudden cardiac 
www.intechopen.com
 Prevention of Sudden Cardiac Death in Patients with Cardiomyopathy 
 
143 
death in the ICD group compared to the medical therapy group (HR = 1.75; 95% CI, 1.11 
to 2.76; P=0.02). 
The second trial is the Immediate Risk Stratification Improves Survival (IRIS) Trial, 
which was a randomized, open label multicenter trial that studied the benefit of ICD 
therapy early after MI compared to optimal medical therapy. Patients were included if 
they had a history of myocardial infarction (5 to 31 days after MI), LVEF < 40% with 
either a baseline heart rate of > 90 bpm, non-sustained VT at >150 bpm on holter or both. 
A total of 898 patients were enrolled in the trial. Mean follow up was for 37 months, and 
almost 75% of the patients underwent revascularization. Most of the patients were on 
beta blockers (97% in the ICD group and 95% in the control group) and angiotensin 
receptor blockers (90% in ICD group and 91.1% in the control group). There was no 
difference in overall mortality between ICD group and the medical treatment group (HR 
1.04, 95% CI of 0.81 to 1.35, p=0.78) (Steinbeck et al. 2009). Patients assigned to ICD 
therapy had lower incidence of sudden cardiac death (HR 0.55, 95% CI of 0.31 to 1.00,  
p = 0049) but higher incidence of non-sudden cardiac death (HR 1.92, 95% CI of 1.29 to 
2.84).  
The reasons for the lack of benefit of ICD therapy early after MI might never be known. 
Revascularization has a protective effect and leads to reverse remodeling especially if done 
in a timely fashion early after MI. Patients who died early in DINAMIT had pump failure. 
Other possibilities include side effects for ICD implantation early after MI or the negative 
effects of shocks or antitachycardia pacing on myocardial contractility.  
In summary, the above trials support the use of ICD therapy for primary prevention of SCD 
in chronic ischemic cardiomyopathy. For patients who suffered a recent MI (<40 days), both 
IRIS and DINAMIT showed a decrease in arrhythmic death but no difference in all cause 
mortality. Currently, the guidelines support ICD therapy in patients with CAD who are > 40 
days post MI and have LVEF < 35%. 
Table 3 summarized the primary prevention trials in patients with coronary artery 
disease.  
2.2.2 Primary prevention of SCD in patients with non-ischemic cardiomyopathy 
The early trials examining the effects of ICD therapy compared to antiarrhythmic 
therapy in patients with non-ischemic cardiomyopathy (NICM) were small and not 
powered enough to show mortality benefit. The first trial is the Amiodarone versus 
Implantable Cardioverter Defibrillator Trial (AMIOVERT) which compared ICD 
therapy in 103 patients with NICM (with the diagnosis made > 6 months before 
enrollment) and non-sustained VT to amiodarone. The primary endpoint was all cause 
mortality. There was no difference in survival between the ICD group and the 
amiodarone group. The trial was terminated due to futility. The second trial is the The 
Cardiomyopathy trial (CAT) which was carried out in Germany and enrolled 104 
patients with non-ischemic cardiomyopathy who were diagnosed within 9 months of 
enrollment. Mean follow up was 5.5 years and the primary end point was all cause 
mortality. Again there was no difference in survival between the ICD group and the 
control group. Both AMIOVERT and CAT trials were underpowered to detect a 
difference between groups, and in both of them the observed mortality was far lower 
than the predicted mortality used to design these trials.  
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Trial N Inclusion Criteria 
Primary 
Endpoint 
Age 
Mean 
LVEF 
NYHA 
Class 
HR  
(95% CI) 
P 
Value 
First Multicenter 
Automatic 
Defibrillator 
Implantation 
Trial (MADIT-I) 
196 
NYHA I-III HF 
LVEF<35% 
 MI > 4 weeks 
CABG > 3 months 
spontaneous NSVT 
and inducible VT 
All cause 
mortality 
63 26% 
I, II and 
III 
0.46  
(0.26 to 
0.82) 
0.009 
Multicenter 
Unsustained 
Tachycardia 
Trial (MUSTT) 
704 
NYHA I-III 
LVEF <40% 
MI>4 days 
spontaneous NSVT 
and inducible VT 
Cardiac 
arrest or 
death from 
arrhythmia 
65 28% 
I, II and 
III 
0.73  
(0.53 -0.99) 
0.04 
The Coronary 
Artery Bypass 
Graft-Patch Trial 
(CABG-Patch) 
1055 
LVEF < 36%, 
Abnormal SAECG, 
undergoing CABG 
All cause 
mortality 
64 27%  
1.06  
(0.81 to 
1.42) 
0.64 
Second 
Multicenter 
Automatic 
Defibrillator 
Implantation 
Trial (MADIT-
II) 
1232 
NYHA I-III,  
LVEF < 30%  
MI > 1 month 
All Cause 
mortality 
64 23% 
I, II and 
III 
0.69  
(0.53 to 
0.93) 
0.02 
Defibrillators in 
Acute 
Myocardial 
Infarction Trial 
(DINAMIT) 
674 
NYHA I-III 
 LVEF <35% 
recent MI (6-40 
days) with 
depressed heart rate 
variability or 
elevated average 
Hear rate over 24 hrs 
All Cause 
mortality 
62 28% 
I, II and 
III 
1.08  
(0.76 to 
1.55) 
0.66 
the Immediate 
Risk 
Stratification 
Improves 
Survival (IRIS) 
898 
NYHA I-III 
LVEF <40% 
Recent MI (5 to 31 
days after MI), with 
either a baseline 
heart rate of > 90 
(bpm) or NSVT at 
>150 bpm on holter 
or both 
All Cause 
mortality 
62 30% 
I, II and 
III 
1.04  
(0.81 to 
1.35) 
0.78 
Table 3. Primary prevention trials of ICD therapy in patients with coronary artery disease. VT 
is for ventricular tachycardia, VF is for Ventricular Fibrillation, NSVT is for non sustained VT, 
LVEF is for left Ventricular ejection Fraction. HR is for hazard Ratio, CI is confidence interval.  
The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation Trial 
(DEFINITE) studied the efficacy of ICD therapy to prevent all cause mortality in patients with 
LVEF < 35% and non-sustained VT or frequent premature ventricular contractions (PVCs) on 
ambulatory monitoring (Kadish et al. 2004). A total of 488 patients (229 in the ICD group and 
229 in the conventional treatment group) were enrolled and the primary end point was death 
from any cause and the secondary endpoint was sudden cardiac death. Most of the patients 
were receiving beta blocker (85%) and ACE-I (86%) There was a 35% relative risk reduction in 
mortality in the ICD group compared to the medical therapy group (HR, 0.65; 95% CI, 0.40 to 
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1.06; P=0.08) but it did not reach statistical significance. A significant reduction in SCD was 
observed (HR 0.20; 95% CI, 0.06 to 0.71; P=0.006). The DEFINITE trial didn’t specify duration 
of heart failure as an entry criterion and it only required absence of a reversible cause of 
cardiomyopathy for enrollment. Patients in DEFINITE who had a recent diagnosis of non-
ischemic cardiomyopathy (Using a 3 months cut point or a 9 months cut point) had similar 
benefit from ICD therapy when compared to patients who had a remote diagnosis of non-
ischemic cardiomyopathy (p0.25) (Kadish et al. 2006) 
The largest trial conducted to examine the effects of ICD therapy on sudden cardiac death 
prevention in patients with ischemic and non-ischemic cardiomyopathy is the Sudden 
Cardiac Death-Heart Failure (SCD-HeFT) trial. This trial enrolled 2521 patients with LVEF 
< 35%, NYHA II-III and it had similar proportion of patients with ischemic cardiomyopathy 
(52%) and non-ischemic cardiomyopathy (48%). Patients were randomized to receive a 
single chamber ICD (n=829), Amiodarone (n=845) or placebo (n=847) (Bardy et al. 2005). 
Patients with recent MI or revascularization (<1 month) were not eligible. Nearly 96% of 
patients were on ACE-I or angiotensin receptor blockers and 69% were receiving beta-
blocker therapy. The primary endpoint was all cause mortality. The ICD group was 
programmed to shock therapy only. After mean follow up of 45.5 months, the ICD group 
had lower mortality compared to placebo (HR 0.77, 95% CI of 0.62-0.96, p=0.007) while 
amiodarone had no effect on mortality compared to placebo (HR 1.06, 95% CI 0.86 to 1.30, 
p=0.53) (Figure 2). Annual rate of appropriate ICD shocks occurred in 68% of patients with 
an average annual rate of 5.1%. The absolute reduction in mortality was similar in patients 
with ischemic (7.2%) and non-ischemic cardiomyopathy (6.5%).  
 
 
Fig. 2. Kaplan-Meier Estimates of Death from Any Cause. CI denotes confidence interval. 
(From Bardy, G. H., Lee, K. L., Mark, D. B., et al. (2005). "Amiodarone or an implantable 
cardioverter-defibrillator for congestive heart failure." New England Journal of Medicine 
Vol. 352, No.3, (January, 2005): pp. 225-237, ISSN 1533-4406, with permission). 
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In a pooled analysis of 10 primary prevention trials (AMIOVERT, MADIT-I, MUSTT, 
MADIT-II, CABG PATCH, CAT, SCD-HeFT, COMPANION, DEFINITE and DINAMIT), 
ICD therapy was associated with 25% relative risk reduction of all cause mortality (RRR 9% 
to 37%, p=0.003) compared to the medical treatment group. The absolute risk reduction was 
7.9%, which means 13 ICDs need to be implanted to save one life over about 3 years. This 
was not sensitive to removal of the any of the trials from the analysis. The benefit of ICD 
therapy in sudden cardiac death prevention is above and beyond the mortality benefit 
associated with use of beta blocker and ACE-I in patients with systolic heart failure 
(Nanthakumar et al. 2004). Table 4 summarized the primary prevention trials of ICD 
therapy in patients with non-ischemic cardiomyopathy. 
 
Trial (N) N Inclusion Criteria 
Primary 
Endpoint 
Age 
Mean 
LVEF 
NYHA 
Class 
HR  
(95% CI) 
P 
Value 
Amiodarone 
Versus 
Implantable 
Cardioverter 
Defibrillator 
Trial 
(AMIOVERT) 
103 
NYHA I-IV 
 LVEF < 35% 
 Dilated 
cardiomyopathy, 
NSVT 
All cause 
mortality 
52 23% 
I, II ,III 
and IV 
 0.80 
Cardiomyopathy 
Trial (CAT) 
104 
NYHA II-III, LVEF < 
30%, Dilated 
cardiomyopathy, 
Recent onset heart 
failure < 9 months 
All cause 
mortality 
52 24% 
II and 
III 
 0.54 
The 
Defibrillators in 
Non-Ischemic 
Cardiomyopathy 
Treatment 
Evaluation Trial 
(DEFINITE) 
488 
NYHA I-III, LVEF < 
35%, Dilated 
cardioyopathy, NSVT 
or frequent PVCs 
(>10 PVC /hr) 
All cause 
mortality 
58 21% 
I, II 
and III 
0.65  
(0.40 to 
1.06) 
0.08 
Sudden Cardiac 
Death-Heart 
Failure (SCD-
HeFT) trial 
2521 
NYHA II-III, EF< 
35%, non-recent MI 
or revascularization 
(>1 month), non-
recent heart failure 
onset (> 3 months) 
All Cause 
mortality 
60 25% 
II and 
III 
0.77  
(0.62-0.96) 
0.007 
Table 4. Primary prevention trials of ICD therapy in patients with non-ischemic 
cardiomyopathy. VT is for ventricular tachycardia, VF is for Ventricular Fibrillation, PVC is 
for premature ventricular contractions, LVEF is for left Ventricular ejection Fraction. HR is 
for hazard Ratio, CI is confidence interval.  
2.2.3 Cost effectiveness of ICD therapy 
ICD therapy adds to the costs of care of patients with cardiomyopathy. Analysis of cost 
effectiveness in the SCD-HeFT trial showed that ICD therapy is cost effective, with 
incremental cost of $38,400 (95% CI of $25,217 to $80,160). This was similar in patients with 
ischemic and non-ischemic cardiomyopathy (Mark et al. 2006). In a pooled analysis of eight 
primary prevention trials, ICD therapy was not found to be cost effective in CABG PATCH 
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and in DINAMIT, which are the trials that showed no mortality benefit from ICD therapy 
compared to conventional medical therapy. When examining the primary prevention trials 
that showed mortality benefit (MADIT-I, MUSTT, MADIT-II, COMPANION, DEFINITE 
and SCD-HeFT), ICD therapy was found to be cost effective, adding between 1.01 and 2.99 
quality-adjusted life years with costs ranging from $34,000 to $70,200. This analysis takes 
into account that the ICD generator will be replaced every 5 years and assumes that the 
mortality benefit persists throughout the patient’s life time (Sanders et al. 2005). Careful 
patient selection with a focus on patients who best fit the trials and are likely to die from 
arrhythmia and not from other non cardiac causes is important to insure the best utilization 
of this important and life saving therapy.  
3. Defibrillator therapy in less common types of cardiomyopathy 
Some of the inherited cardiomyopathies carry an increased risk of sudden cardiac death. We 
will review in this section the data behind ICD therapy in patients with two inherited 
disorders, first is Hypertrophic cardiomyopathy (HCM) and the second is arrhythmogenic 
right ventricular dysplasia./ cardiomyopathy (ARVD/C). 
3.1 Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy is an autosomal dominant disorder diagnosed by two-
dimensional echocardiography and is characterized by hypertrophied and non-dilated LV in 
the absence of other causes of hypertrophy (no history of hypertension or aortic stenosis or any 
other cardiac or systemic disease causing hypertrophy) (Maron 2002; 2003). Histologically, 
there is myocardial disarray, abnormal microvascular circulation with mismatch between 
myocardial mass and blood supply as well as interstitial fibrosis (Maron et al. 1986; Varnava et 
al. 2001). All of these predispose to ventricular tachycardia and ventricular fibrillation putting 
the patients at risk of sudden cardiac death (Varnava et al. 2001). The disease can present at 
any age in life. Earlier registries from tertiary care centers overestimated the risk of sudden 
cardiac death due to selection bias (with the annual risk of death thought to be 3 to 6%). More 
recent population studies of unselected patients from community centers suggest a more 
benign prognosis (annual risk of death of 1%) (Maron et al. 1999; Kofflard et al. 2003). Despite 
all recent data, there is a subset of patients with HCM who are at high risk of sudden cardiac 
death. In fact HCM remains the most common etiology for SCD in patients younger than 40 
years and it can be the first presentation in patients with HCM (Maron 2003). Patients who 
survived a cardiac arrest are particularly at high risk of dying suddenly. Data from registries 
suggest a number of markers that increase the risk of sudden cardiac death. These markers 
include one or more of the following: LV wall thickness > 30 mm (Maron et al. 1999), syncope 
(particularly exertional syncope) (Kofflard et al. 2003), family history of SCD, non-sustained 
VT on ambulatory holter of > 120 bpm and a blunted blood pressure response to exercise. 
High LV outflow gradient (> 30 mmHg) has also been considered as risk marker for sudden 
cardiac death (Maron et al. 2003).  
There are no randomized trials examining the benefits of ICD therapy in this patient 
population, so the data supporting ICD therapy is derived from registry data in patients 
with HCM who received an ICD when found to be high risk by their treating cardiologist / 
Electrophysiologist (Maron et al. 2000). The last update from the registry included 506 
patients with HCM with a mean age of 42 years. Patients received and ICD if they had 
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survived a cardiac arrest due to ventricular tachycardia or ventricular fibrillation (secondary 
prevention cohort of 123 patients) or if they had one or more risk factors of sudden cardiac 
death: unexplained syncope, family history of sudden cardiac death in one or more first 
degree relatives, massive LV hypertrophy or non-sustained VT on holter monitoring 
(Primary prevention cohort of 383 patients) (Maron et al. 2007). Based on this registry, 
patients with HCM who survived cardiac arrest have a high appropriate ICD discharges 
(10.6% per year). This risk is lower in patients with HCM who had an ICD for primary 
prevention (3.6% per year). A third of these patients were 30 years or younger. Amiodarone 
was used based on the physicians judgment and it did not prevent arrhythmia occurrence 
(27% of patients who were on amiodarone had appropriate shocks). A third of the patients 
who received an ICD for primary prevention and had appropriate ICD discharges had one 
risk factor only for sudden cardiac death. There was no difference between the risk factors in 
the prediction of SCD. Since this is a young population of patients, they are at risk of 
inappropriate shocks, which occurred in 27% of the patients and were mainly due to sinus 
tachycardia, atrial fibrillation or lead malfunction. ICD implantation was shown to be safe 
with a rate of infection of 3.8% and the rate of lead fracture or dislodgement of 6.7%. 
Implantation of ICD has become an acceptable therapy in patients with HCM who survived 
cardiac arrest or who have two or more of the aforementioned risk factors of sudden cardiac 
death. For patients with only one risk factor of sudden cardiac death, the decision to implant 
an ICD is left to the physician’s judgment and a careful discussion with the patient and his / 
her family in regards to the risks, benefits and alternatives of ICD therapy. In our 
experience, the presence of only one risk factor for SCD does not guarantee a 
recommendation for implanting an ICD. The clinical scenario is to be taken into account, as 
well as the patient’s age and his / her wishes. The decision to implant is more favorable in a 
young patient with HCM with family history of sudden cardiac death or in a young patient 
with severe LV wall thickness (>30 mm) but still the discussion should take into account the 
young age of the patient and his / her wishes. On the other hand the discussion is more 
careful in an old patient with HCM in his / her 60s with history of non-exertional syncope 
that seems to be vasovagal in origin, the fact that the patient survived to that age without 
any major cardiac arrest indicates a more benign prognosis. Table 2 lists the current 
recommendations for ICD implantation for patients with hypertrophic cardiomyopathy.  
3.2 Arrhythmogenic Right Ventricular Dysplasia / Cardiomyopathy (ARVD/C) 
Arrhythmogenic right ventricular Dysplasia/ Cardiomyopathy (ARVD/C) is an inherited 
myopathy characterized by fibrofatty infiltration of the right ventricular (RV) wall, with left 
ventricular involvement over time in some patients (Gemayel et al. 2001; Sen-Chowdhry et al. 
2004). The RV wall becomes thin, and the most areas affected are the RV inflow, apex and RV 
outflow, which form what is called the triangle of dysplasia. Ventricular tachycardia in general 
has left bundle branch morphology and is caused by macro-reentry and there is evidence that 
adrenergic stimulation acts as a trigger for these arrhythmias (Leclercq et al. 1996). ARVC/D 
accounts for 3 to 10% of death occurring in patients younger than 65 years (Tabib et al. 2003) 
and is one of the causes of sudden cardiac death in athletes (Maron 2003). The Most common 
presentation is with palpitations (due to frequent ventricular ectopy and ventricular 
tachycardia), chest pain, and syncope (mostly exertional). With time patients might develop 
RV dilatation, LV involvement and heart failure. Most of the data are obtained from registries 
in the United States and Europe (either single centers or multicenter registries). Diagnosis of 
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ARVD/C is based on the European Task Force criteria (McKenna et al. 1994). Risk factors of 
sudden cardiac death include prior cardiac arrest, hemodyamically unstable VT and prior 
syncope. Some studies suggested that LV involvement, development of heart failure and 
marked RV dilatation are risk factors for sudden cardiac death (Hulot et al. 2004). The role of 
electrophysiologic testing in risk stratification is less clear, with some studies showing a high 
positive predictive value and some showing low positive and low negative predictive values 
in predicting arrhythmias and appropriate ICD shocks (Corrado et al. 2003; Roguin et al. 2004). 
Beta blockers and sotalol were thought to be the best in suppressing these arrhythmias; 
however, this is challenged in more recent studies (Marcus et al. 2009). ICD therapy is clearly 
indicated in patients who survived cardiac arrest or have sustained VT and is a class IIa 
indication in patients with ARVD/C who have unexplained syncope. Some patients 
experience repetitive shocks requiring administration of antiarrhythmic drug therapy as well 
as VT ablation. Since this is a young population, they are also likely to experience 
inappropriate shocks due to sinus tachycardia or other supraventricular arrhythmias. In 
general ICD therapy is life saving and is well tolerated and has become accepted standard of 
care in patients with ARVD/C who experience cardiac arrest, sustained VT, unexplained 
syncope or marked RV dilatation or LV involvement (Epstein et al. 2008). Table 2 lists the 
current guidelines for ICD implantation in this patient population.  
4. Cardiac Resynchronization Therapy (CRT) in patients with heart failure and 
its effects on mortality 
Cardiac Resynchronization Therapy (CRT) aims at correcting mostly intraventricular 
dyssynchrony by stimulating the left ventricle (preferably basal stimulation) or by 
simultaneously stimulating the left and right ventricles after a sensed or paced atrial beat or 
during atrial fibrillation. CRT has been shown to improve the cardiac hemodynamics in 
patients with systolic heart failure, including improvements in the systolic blood pressure 
and decrease in the pulmonary capillary wedge pressure (by up to 20% in some patients) 
(Blanc et al. 1997). The early trials had endpoints related to heart failure functional status 
(including the 6 minute walk test, NYHA functional class), LV systolic function and 
improvement in the LV dimensions (including LVEF, LV end systolic volume and LV end 
systolic volume index as well as LV end diastolic dimension). Other studies relied on clinical 
composite score (which combines death from any cause, recent hospitalization for heart 
failure, NYHA class as well as the global assessment score) to define response to CRT 
(Chung et al. 2008). However, there is poor correlation between clinical and 
echocardiographic measurements of response and there is disagreement about the best way 
to measure response in patients with heart failure receiving CRT (Fornwalt et al.). So far 
QRS duration remains an important criterion for patient selection for CRT. Kass and 
colleagues demonstrated that baseline QRS duration correlated with enhancement in the 
isovolumetric dP/dtmax (r = 0.6, p = 0.02), while changes in the QRS duration with pacing 
did not predict hemodynamic response (Nelson et al. 2000). Most of the trials on CRT 
involved patients with systolic heart failure with LVEF < 35% and NYHA class III or IV as 
well as a QRS duration of > 120 msec. A trial studying patients with narrow QRS in patients 
with systolic heart failure failed to show any benefit. Later studies included patients with 
NYHA class I and class II heart failure with endpoints related to death or hospitalization. 
This section will focus mainly on the studies that included mortality as an endpoint.  
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4.1 Cardiac resynchronization therapy trials in patients with moderate to severe heart 
failure 
The Multicenter InSync Randomized Clinical Evaluation (MIRACLE) trial involved 
implanting a CRT only device (with biventricular pacing only, no Defibrillator component). 
Patients were randomized if they had an LVEF < 35% and NYHA functional class III or IV 
heart failure despite optimal medical therapy and QRS duration of > 130 milliseconds 
(msec). a total of 453 patients were randomized after successful implantation of a CRT 
device to CRT ON (228 patients) and CRT OFF (225 patients) status for a period of 6 months 
(Abraham et al. 2002). The primary endpoint included the 6 minute walk test, quality of life 
score and NYHA class. A total of 453 patients were enrolled in the study. Patients assigned 
to CRT ON had 13% improvement in the 6-minute walk and in the quality of life score. The 
secondary endpoints also improved in the CRT ON arm including improvement in LVEF as 
well as peak oxygen consumption (VO2). The protocol specified safety variables that 
included an analysis of death or worsening heart failure. There was no difference in overall 
mortality (HR 0.73, 95% CI 0.34 to 1.54, p=0.40) but there was a decrease in hospitalization 
(HR 0.50, 95% CI 0.28 to 0.88, p= 0.02). The study did not specify mortality as a primary end 
point and was not powered enough to show differences in mortality.  
The Multicenter Insync ICD randomized Clinical Evaluation (MIRACLE ICD) trial had a 
similar design to the MIRACLE study. Patients were included if they had LVEF < 35%, 
NYHA class III to IV despite optimal medical therapy and QRS duration of > 130 
milliseconds and were at high risk of death from ventricular arrhythmias (Young et al. 
2003). Almost two thirds of patients had an ischemic etiology and at least 60% were on beta 
blockers. All patients received a CRT-D device (total of 369 patients) of whom 182 had CRT 
OFF (controls) and 187 had CRT ON. At 6 months follow up, all patients with the CRT ON 
showed an improvement in the NYHA class (p=0.007) and the quality of life score (p=0.02). 
There was no difference in 6-minute walk distance (p=0.36) compared to the control group. 
Of the secondary endpoints, There was an improvement in the peak VO2 (p=0.04) and a 
trend towards reductions in the LV end systolic and end diastolic dimensions (p=0.06 for 
both) compared to the control group. The study did not show any difference in mortality 
(p=0.96) or hospitalization (p=0.69) between the two groups. Similar the to MIRACLE study, 
the MIRACLE ICD study had short follow up and was not powered enough to detect 
difference in mortality.  
The CONTACT CD Biventricular Pacing study enrolled 490 patients with LVEF <35%, 
QRS > 120 msec and NYHA class II to IV despite optimal medical therapy and conventional 
indications for ICD implantation. Patients were assigned to CRT ON (245 patients) and CRT 
OFF (245 patients) for up to 6 months (Higgins et al. 2003). The primary endpoint was 
progression of heart failure, defined as all cause mortality, hospitalization for HF and 
ventricular tachycardia or ventricular fibrillation requiring device intervention. Secondary 
endpoints included peak oxygen consumption (VO2), 6-minute walk, NYHA class, quality 
of life as well as echocardiographic analysis. Patients with CRT ON had a 15% reduction in 
the composite HF progression but this was not statistically significant (p=0.35). However, 
patients with NYHA class III and IV had an improvement in the peak VO2 (p=0.003), 6-
minute walk (p=0.03), NYHA class (p=0.0006) and QOL (0.02). Patients who had NYHA 
class I or II didn’t show any improvement in any of the secondary parameters. One 
important finding in CONTACT CD trial is that patients with CRT ON had significant 
reductions in LV internal diameter in diastole (LVIDd) (p<0.001) LV internal diameter in 
systole (LVIDs) (p<0.001), and LVEF (p=0.02). Even patients with NYHA II had significant 
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improvement in the LV dimensions with CRT ON. The study was not adequately powered 
to detect a statistical difference in the primary endpoint of composite HF progression. This 
was due to the fact that the observed event rates were half the expected while designing the 
trial.  
The Comparison of Medical Therapy, Pacing and Defibrillation on Heart Failure Study 
(COMPANION) enrolled 1520 patients with LVEF< 35%, NYHA class III or IV heart failure 
despite optimal medical therapy and QRS duration of > 120 msec in a 1:2:2 fashion to 
medical therapy versus biventricular pacing alone (CRT only) versus biventricular pacing 
with defibrillation (CRT-D) (Bristow et al. 2004). Almost 59% of the patients had ischemic 
cardiomyopathy and 82% were NYHA class III. The primary endpoint was death or 
hospitalization for any cause while the secondary endpoints included death from any cause. 
As compared to the medical therapy group, patients with CRT only (Biventricular 
pacemaker only) decreased the risk of death or hospitalization from any cause (HR 0.81, 
p=0.014) as did CRT-D group (biventricular defibrillator group) (HR 0.80, p-0.01). CRT only 
decreased the risk of death by 24% (p=0.059) while CRT-D decreased the risk of death by 
36% (p=0.003). COMPANION was the first trial to show that CRT improves the quality of 
life, symptoms as well as decrease the risk of death or hospitalization for heart failure.  
The Cardiac Resynchronization-Heart Failure Study (CARE HF) randomized 813 patients 
with LVEF < 35%, NYHA class III to IV heart failure despite optimal medical therapy and 
QRS duration > 120 msec (patients with QRS between 120 to 149 msec had to have two of 
the three echocardiographic parameters of dys-synchrony: an aortic pre-ejection delay of > 
140 msec, an interventricular mechanical delay of > 40 msec or delayed activation of the 
posterolateral wall of the LV (Cleland et al. 2005). Patients assigned to the CRT group 
received biventricular pacemaker (no defibrillators). The primary endpoint was the 
composite of death or unplanned hospitalization for a major cardiovascular event. 
Secondary endpoint was death from any cause. Other secondary endpoints included quality 
of life, improvement in NYHA class and echocardiographic parameters (mainly ventricular 
function, mitral regurgitation). After a mean follow up of 29.4 months, patients treated with 
CRT (total of 409 patients) had less death or hospitalization for cardiovascular event (HR 
0.63, 95% CI 0.51 to 0.77, p< 0.001) compared to patients with medical therapy only (404 
patients). CRT also improved survival (HR 0.64, 95% CI 0.48 to 0.85, p< 0.002) (Figure 3). 
Patients with CRT had improvement in NYHA class, better QOL, and showed smaller area 
of mitral regurgitation and an improvement in the LVEF at 3 and 18 months post CRT. 
CARE HF was the first CRT only trial to show that biventricular pacing alone can improve 
survival. The lack of mortality benefit from CRT only arm in COMPANION might be due to 
the fact that patients in COMPANION trial were sicker, with over 55% having ischemic 
cardiomyopathy with mean LVEF of 22% while patients in CARE HF had a mean LVEF of 
25% and only a third of them had ischemic cardiomyopathy. The added benefits of CRT on 
survival will be examined later by the RAFT study.  
The Cardiac Resynchronization Therapy in Patients with Heart Failure and Narrow QRS 
(RethinQ) study randomized 172 patients with history of NYHA class III heart failure, 
LVEF <35% despite optimal medical therapy and QRS duration of <130 msec with evidence 
of mechanical dys-synchrony on echocardiography (defined as septal to lateral or septal to 
inferior wall delay >65 msec as measured by tissue doppler or septal to posterior wall delay 
>130 msec as measured by M Mode echocardiography (Beshai et al. 2007). Primary outcome 
was the improvement of peak oxygen consumption of > 1 ml per kilogram of body weight 
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Fig. 3. Kaplan-Meier Estimates of the Time to the Primary End point of death or unplanned 
hospitalization for a major cardiovascular event (Panel A) and Death from any cause (Panel 
B). (From Cleland, J. G., Daubert, J. C., Erdmann, E., et al. (2005). "The effect of cardiac 
resynchronization on morbidity and mortality in heart failure." New England Journal of Medicine, 
Vol. 352, No.15, (April, 2005): pp. 1539-1549, ISSN 1533-4406, with permission).  
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per minute during cardiopulmonary exercise testing. The secondary outcomes were 
improvements in the 6 minute walk test, NYHA class and quality of life. All patients had 
a CRT device implantation and were assigned to CRT ON (n=76) or no CRT (n=80). After 
follow up of 6 months, there was no difference in the primary endpoint between patients 
with CRT and patients with no CRT (46% vs 44%, p=0.63). Patients in the CRT group 
with a QRS > 120 msec had significant improved in peak oxygen consumption at 6 
months follow up (0.02) but patients in the CRT group with QRS <120 msec didn’t have 
improvement in peak oxygen consumption at 6 months (p=0.45). There was no 
improvement in the quality of life measures (as measured by Minnesota living with 
Heart failure questionnaire) and in the 6-minute walk test in both groups of patients 
regardless of the QRS duration. Patients with CRT on had an improvement in the NYHA 
class at 6 months compared to patients with no CRT regardless of the QRS duration 
(p=0.006). 
4.2 Cardiac resynchronization therapy trials in patients with mild heart failure 
The Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction 
Study (REVERSE) trial was the first CRT trial to include patients with NYHA II and 
asymptomatic NYHA class I patients with LV dysfunction. A total of 610 patients 
underwent CRT device implantation and were randomized to CRT ON (419 patients) and 
CRT OFF (191 patients). Inclusion criteria included LVEF <40%, NYHA functional class I or 
II heart failure with a QRS 120 msec (Linde et al. 2008). Mean follow up was for 12 months. 
The primary end point was the heart failure (HF) clinical composite response (which 
included heart failure hospitalization, NYHA class and global assessment score). Secondary 
endpoints included LV end-systolic volume index and hospitalization for worsening HF. 
There was no difference between the two groups in the HF clinical composite score (which 
compared only the percent worsened) (p = 0.10). Patients assigned to CRT-ON experienced a 
greater improvement in LV end-systolic volume index (–18.4 ± 29.5 ml/m2 vs. –1.3 ± 23.4 
ml/m2, p < 0.0001) and had a 53% relative risk reduction in time to first HF hospitalization 
(p=0.03). There was no difference between the two groups in the 6- minute walk test and in 
the quality of life scores. The improvement in LV end systolic volume index was similar in 
patients with NYHA I and NYHA II. The rate of LV lead implantation related complications 
was 10%. These complications were mostly due to LV lead dislodgement or diaphragmatic 
stimulation.  
The Multicenter Automatic Defibrillator Implantation Trial with Cardiac 
Resynchronization therapy (MADIT-CRT) randomized 1820 patients with LVEF <30%, 
NYHA class I or II HF and QRS duration of > 130 msec in a 3:2 design to cardiac 
resynchronization therapy with defibrillation capacity (CRT-D) (1089 patients) and to 
ICD only group (731 patients). The primary endpoint was death from any cause or 
hospitalization for heart failure (Moss et al. 2009). Secondary endpoints included death 
from any cause and heart failure hospitalization alone. Follow up was for 4.5 years. 
Patients who received CRT-D had lower risk of death or hospitalization for heart failure 
(HR 0.66, 95% CI of 0.52 to 0.84, p=0.001) compared to the ICD only group. There was no 
difference in death from any cause between the two groups (HR 1.00, 95% CI of 0.69-1.44, 
p=0.99). The rate of hospitalization was significantly lower in the CRT-D group 
compared to the ICD only group (HR 0.59, 95% CI of 0.47 to 0.74, p<0.001). Patients with 
ischemic and non-ischemic cardiomyopathy benefited similarly from CRT. Subanalysis 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
154 
of MADIT CRT showed that female patients (n=453, 25%) were more likely to have non-
ischemic cardiomyopathy and left bundle branch block (LBBB) compared to male 
patients. Female patients were more likely to have reverse remodeling by 
echocardiography and had a 69% relative risk reduction of death or heart failure (HR of 
0.31, p<0.001) (Arshad et al.). Patients with QRS duration > 150 msec had greater benefit 
from CRT (HR 0.48, 95% CI 0.37 to 0.64) compared to patients with QRS duration < 150 
msec (HR 1.06, 95% CI 0.74 to 1.52, p=0.001 for interaction). Patients assigned to the CRT-
D arm had significant reduction in LV end diastolic volume index (–26.2 versus –7.4 
mL/m2), LV end systolic volume index (–28.7 versus –9.1 mL/m2 ) as well as 
improvement in LVEF (11% versus 3%) compared to the ICD only group. After adjusting 
for baseline variables, for every 10% reduction in the LV end diastolic volume index, 
there was a 40% reduction in the risk of death or heart failure hospitalization (Solomon 
et al.). Furthermore MADIT CRT measured echocardiographic response as a decrease in 
LV end systolic volume > 25%. Using this definition, 529 patients assigned to the CRT-D 
arm responded to CRT and were less likely to have ventricular tachyarrhythmia (VT or 
VF) and inappropriate shocks. Analysis of the data showed that for every 10% reduction 
in LV end systolic volume, there is a 20% decrease in the risk of ventricular 
tachyarrhythmias (p<0.001) even after adjusting for other clinical risk factors including 
age, QRS duration, left bundle branch block, and blood urea nitrogen (BUN) (Barsheshet 
et al.).  
The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) 
randomized 1798 patients with LVEF <30%, NYHA II to III heart failure and QRS duration 
of >120 msec or a paced QRS duration of > 200 msec to either ICD alone or Biventricular 
defibrillator (CRT-D) (Tang et al.). Mean follow up was for 40 months and the primary 
endpoint was death or hospitalization for heart failure while secondary endpoints included 
death from any cause, death from cardiovascular cause and heart failure hospitalization. 
Most of the patient had NYHA class II (80%) and had ischemic etiology (64%). Patients with 
CRT-D had less death and heart failure hospitalization compared to the ICD group (HR 0.75, 
95% CI of 0.64 to 0.87, p <0.001). CRT-D also improved survival compared to ICD alone (HR 
0.75, 95% CI 0.62-0.91, p=0.003) (Figure 4). There was less heart failure hospitalizations with 
CRT-D group compared to ICD only group (HR 0.68, 95% CI of 0.56 to 0.83, p<0.001). There 
was no difference in the primary and secondary endpoints in patients with ischemic and 
non-ischemic cardiomyopathy. Patients with wider QRS (>150 milliseconds) had better 
survival than patients with QRS < 150 msec. However, patients with CRT-D had more 30 
days adverse events compared to the ICD alone group (p<0.001), these were mostly device 
related complications.  
These trails established CRT as an important therapy for patients with heart failure, LVEF < 
35% and NYHA class III to IV. The only measure of dys-synchrony that stood the test of 
time is the QRS duration. Even though there is disagreement in the literature in the 
measurement of “response”. At least two thirds of patients with CRT show clinical 
improvement in their functional status. CRT has been proven to improve survival 
independently as shown in the CARE HF trial, and it also improves survival above and 
beyond ICD therapy as shown in the RAFT trial. The guidelines for implantation for CRT in 
patients with systolic heart failure are listed in Table 5. These guidelines were written in 
2008, and do not reflect the recent evidence of the benefits of CRT in milder forms of heart 
failure that was found in the REVERSE, MADIT CRT and RAFT trials.  
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Fig. 4. Kaplan Meier Estimates of Death or Hospitalization for Heart Failure (Panel A) and 
Death from Any Cause (Panel B). (From Tang, A. S., Wells, G. A., Talajic, M., et al. "Cardiac-
resynchronization therapy for mild-to-moderate heart failure." New England Journal of 
Medicine Vol. 363, No.25, (December, 2010): pp. 2385-2395, ISSN 1533-4406, with 
permission) 
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Class I (General agreement of benefit of CRT) 
1. CRT with or without an ICD is indicated for the treatment of for patients are in sinus 
rhythm who have LVEF ≤ 35%, a QRS duration ≥ 120 milliseconds, NYHA functional 
Class III or ambulatory Class IV heart failure symptoms with optimal recommended 
medical therapy.  
Class IIa (Weight of evidence is in favor of CRT) 
1. CRT with or without an ICD is indicated for patients  in sinus rhythm who have 
LVEF ≤ 35%, a QRS duration ≥ 120 msec, NYHA functional class III or ambulatory 
class IV heart failure symptoms with optimal recommended medical therapy. 
2. CRT is reasonable for patients with LVEF ≤ 35%, QRS duration ≥120 milliseconds, 
NYHA functional Class III or ambulatory Class IV heart failure symptoms with 
optimal recommended medical therapy and who have frequent dependence on 
ventricular pacing. 
Class IIb (Efficacy of CRT is less well established) 
1. CRT may be considered for patients with LVEF ≤ 35% with NYHA functional Class I 
or II symptoms who are receiving optimal recommended medical therapy and who 
are undergoing implantation of a permanent pacemaker and/or ICD with 
anticipated frequent ventricular pacing. 
Class III (General agreement that CRT is less effective and might be harmful) 
1. CRT is not indicated for asymptomatic patients with reduced LVEF in the absence of 
other indications for pacing.  
2. CRT is not indicated for patients whose functional status and life expectancy are 
limited predominantly by chronic non-cardiac conditions.  
Table 5. Recommendations for cardiac resynchronization therapy based on the 
ACC/AHA/HRS 2008 Guidelines for Device Based Therapy. CRT: Cardiac 
Resynchronization Therapy. ICD: Implantable Cardioverter Defibrillator. NYHA: New York 
Heart Association 
5. Defibrillator shocks, their impact on quality of life and prognosis 
5.1 Impact of defibrillator shocks on quality of life 
From all the studies presented earlier, it is clear that ICD therapy prevents sudden cardiac 
death. However, ICD shocks can be painful and have been shown to affect the quality of life 
in both primary and secondary prevention trials. Patients with ICD can receive 
inappropriate shocks due to atrial fibrillation (AF), supraventricular tachycardia (SVT) or 
inappropriate sensing from the device. The quality of life (QOL) was assessed in the AVID 
trial as a secondary endpoint using the Medical Outcomes Short Form 36 item questionnaire 
(SF-36). Of the 905 patients enrolled in QOL analysis, 800 survived for longer than 1 year. 
Both treatment groups (ICD group versus antiarrhythmic group) had significant 
impairment in both physical functioning and mental well-being(Schron et al. 2002). ICD 
shocks were independently associated with reduction in both physical functioning and 
mental well-being. The CIDS trial also measured QOL, in the 400 patients who survived for 
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> 1 year, patients assigned to the ICD group had an improvement in their quality of life 
scores compared to patients assigned to amiodarone. However, patients having frequent 
shocks (>5 shocks) had reduced QOL.  
The SCD-HeFT trial also collected data on the quality of life using two different scales: The 
Duke Activity Scale Index (DASI) reflecting the overall physical functioning and the SF-36 
Mental Health Inventory 5 which measures psychological well being (Mark et al. 2008). Data 
were collected at baseline, 3, 12 and 30 months of follow up. A total of 2479 patients (98%) 
enrolled in SCD-HeFT completed the quality of life portion of the study. Patients receiving 
ICD therapy and patients assigned to placebo had similar DASI scores and SF-36 MHI 5 
scores at baseline. The psychological well being of patients receiving an ICD was 
significantly better at 3 months and 12 months compared to patients receiving placebo. 
There was no difference in the physical functioning at baseline or at 3, 12 or 30 months in the 
ICD group versus the placebo group. The quality of life of patients who received an ICD 
shock a month before the screening was significantly worse in multiple aspects (physical, 
psychological, social and self related health).  
5.2 Impact of defibrillator shocks on prognosis 
The SCD-HeFT Trial also evaluated the prognostic impact of ICD shocks in patients with 
ischemic and non-ischemic cardiomyopathy. Most of the patients received a single chamber 
ICD programmed to shock only therapy with no antitachycardia pacing involved. (Poole et 
al. 2008). Patients (n=811) were followed for 45.5 months and a third of patients (n=269) 
received ICD shocks. Patients who received appropriate ICD shock (n=128) were at 
increased risk of death (HR 5.68, 95% CI of 3.97 to 8.12, p < 0.001) compared to patients with 
no appropriate shocks. Patients who received inappropriate shocks were also at increased 
risk of death (HR 1.98, 95% CI of 1.29 to 3.05, p=0.002) compared to patients with no 
inappropriate shocks. Atrial fibrillation was the most common reason for inappropriate ICD 
shocks and the most common cause of death in patients receiving any shock was 
progressive heart failure.  
Inappropriate shocks were examined in the MADIT-II trial. Of the 719 patients who received 
an ICD, inappropriate shocks occurred in 83 patients (11.5%). Inappropriate shocks 
represented a third (31.2%) of total shocks (Daubert et al. 2008). Independent predictors of 
inappropriate shocks included atrial fibrillation (HR = 2.9, P<0.01), smoking (HR 2.18, 
P=0.03), diastolic blood pressure of > 80 mmHg (HR = 1.61, P= 0.04) and antecedent 
appropriate shocks (HR = 2.25, P= 0.03). Again, inappropriate shocks were most likely due 
to AF (44%), SVT (36%) or abnormal sensing (20%). Implantation of a dual chamber ICD did 
not decrease the rate of inappropriate shocks compared to single chamber ICD implantation 
(38.6% versus 44% respectively, p=0.31). Any shock whether appropriate or inappropriate 
was associated with significant increase in mortality (HR 4.08, p<0.01). Inappropriate shocks 
were associated with a 2 fold increase in mortality (HR is 2.29, p=0.03) while appropriate 
shocks had a 3 fold increase in mortality (HR 3.36, p<0.01). Electrical instability in the form 
of VT or VF or atrial fibrillation could be markers of deteriorating heart function and pump 
failure(Obadah Al Chekakie 2009). It is unclear if the VT or VF that the patient experiences 
heralds progressive pump failure, or whether the fact that shocks my increase mortality due 
to their negative effect on contractility in this high risk population or if both assumptions are 
true. 
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5.3 Device programming studies: Safety, effectiveness and impact on quality of life 
Since Shocks are associated with lower quality of life and increase mortality, attempts at 
reducing shocks (both appropriate and inappropriate) became the focus of several studies. 
Antitachycardia pacing (ATP) has been shown to terminate 78 to 94% of slow VTs (188 bpm) 
(Peinado et al. 1998). The PAINFREE RX II trial randomized 634 patients with ICDs to 
standardized ATP (n=313 patients) versus shocks (n=321 patients). The programming in the 
Standarized ATP arm included two main parameters: First programming ATP in the fast VT 
zone of 188 to 250 bpm, at 8 pulses and 88% of VT cycle length. Second is extending the 
detection to 18 of 24 beats to avoid shocking ventricular tachycardia that was going to 
terminate anyway. The primary objective was to demonstrate that ATP will not prolong 
treatment > 6 seconds compared to the shock arm. Secondary objectives included the QOL, 
ATP efficacy and acceleration and syncope (Sweeney et al. 2005). After mean follow up of 
11+/- 3 months, 4230 ICD counters were retrieved, and electrograms were only available in 
1827 episodes. A third of the shocks was deemed inappropriate and due to SVT and 0.2% 
were due to noise. Only 73% of total shocks were due to true ventricular arrhythmias. Of 
these, 431 (58%) were detected as VT, 32% as Fast VT and 10% as VF. ATP was successful as 
initial therapy in 81% of the episodes and failed in 54 episodes, of which 49 episodes were 
shocked while 5 were terminated by a second ATP therapy. ATP did not prolong therapy 
duration (median duration was 10 seconds in the ATP arm versus 9.7 seconds in the shock 
arm) and there was no significant difference in the acceleration of VT/VF between the two 
arms. Syncope was very rare in the two arms (2 in the ATP group and 1 in the shock arm) 
and the first shock success was identical between the two arms. There was no difference 
between the two groups at baseline in the QOL scores as assessed by the SF-36. Patients 
assigned to the shock arm had an improvement in the bodily pain scores at 12 months but 
no change in the other SF-36 subscales. While patients assigned to the ATP arm had 
significant improvement in 5 subscales (bodily pain, social functioning, role emotional, 
physical functioning and role physical). This trial established the safety and efficacy of ATP 
in the fast VT zone and the safety of extending the detection duration to 18 out of 24 beats, 
which led to a decrease in shocks (The patients assigned to the shock arm had 147 detected 
FVT episodes with only 99 episodes receiving therapy). This will be an important factor in 
the design and implementation of the PREPARE study.  
The Primary Prevention Parameters Evaluation Study (PREPARE) study compared 700 
patients who had received an ICD or Biventricular defibrillator for primary prevention 
within 6 months of enrollment (Wilkoff et al. 2008). The control group for the ICD patients 
was taken from the EMPIRIC trial while the control group for the Biventricular ICD (BiV 
ICD) arm was from the MIRACLE ICD trial. The cohort of the PREPARE study had the 
following programming parameters: Initial detection for VT at rate of >182 bpm, with ATP 
programmed to fast VT of 182 to 250 bpm, with detection prolonged to 30 of the 40 intervals 
to avoid shocking VT that was going to terminate anyway, programming SVT 
discriminators to arrhythmias < 200 bpm to prevent inappropriate shocks. The primary 
endpoint of the study was the morbidity index defined as 1) device related cardioversion or 
defibrillation whether appropriate or inappropriate, 2) syncope secondary to arrhythmia or 
presumed arrhythmia and 3) untreated sustained symptomatic VT/VF events. The 
PREPARE study patients were less likely to receive a shock for any cause in the first year as 
compared to the control cohort (8.5 % vs 16.9%, p<0.01) and were also less likely to receive 
inappropriate shocks even after correcting for differences in baseline variables including 
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mean LVEF, hypertension, history of ischemic heart disease, syncope and baseline use of 
beta blockers. The morbidity index incidence density was significantly lower in the 
PREPARE cohort compared to the control cohorts (HR 0.26 versus 0.69, 95% CI of 0.2 to 0.72, 
p=0.003). Importantly, only 12 of the 40 syncope episodes were judged to be due to 
arrhythmia, and of those, only 11 were due to PREPARE programming. The PREPARE 
study established the efficacy of empirically programming the ICD detection and therapy to 
minimize both appropriate and inappropriate shocks. This is true for patients receiving ICD 
therapy for primary prevention only. 
In summary: ICD therapy prevents sudden cardiac death but patients who receive an ICD 
shock have increased morbidity and mortality and poor quality of life. Programming the 
device can help minimize ICD shocks, whether appropriate or inappropriate. Patients with 
ICD therapy who receive a shock should be followed closely since they are at increased risk 
of pump failure.  
6. Conclusion 
Implantable cardioverter defibrillator therapy is important in sudden cardiac death 
prevention in patients with ischemic and non-ischemic cardiomyopathy as well as survivors 
of cardiac arrest. Cardiac resynchronization therapy with and without an ICD improves the 
quality of life and leads to reverse remodeling and independently prevents sudden cardiac 
death in patients with QRS > 120 msec and LVEF < 35% who are on optimal medical 
therapy. Defibrillator shocks are associated with adverse outcomes and pump failure. 
Careful patient selection and sophisticated programming can help prevent sudden cardiac 
death without compromising the quality of life of the patients.  
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